| Condition |
Ex vivo NK cell activation |
NK cell source |
Trial Phase |
Participant age range |
ClinicalTrials.gov Identifier |
| AML/MDS |
IL-15 activated |
Haploidentical |
Phase 1 |
> 18 years |
NCT01385423 |
| AML |
Cytokine-induced memory-like NK cells |
Haploidentical |
Phase 1 |
> 18 years |
NCT01898793 |
| AML |
IL-21 activated |
Haploidentical |
Phase 1/2 |
18 – 59 years |
NCT01787474 |
| AML/MDS; T-cell ALL |
Irradiated K562-mb15-41BBL cells and low dose (10 IU/mL) IL-2 |
Family member with at least 3 of 6 HLA match to recipient |
Phase 1 |
6 – 80 years |
NCT02123836 |
| B-lineage ALL |
K562-mb15-41BBL and IL-2; transduced with chimeric antigen receptor (anti-CD19-BB-zeta) |
Family member with at least 3 of 6 HLA match to recipient |
Phase 2 |
6 – 80 years |
NCT01974479 |
| MM |
IL-2 activated |
Umbilical cord blood-derived |
Phase 1/2 |
18 – 75 years |
NCT01729091 |
| Neuroblastoma post anti-GD2 antibody |
IL-2 activated |
Partly matched HLA family member |
Phase 1 |
< 21 years |
NCT01576692 |
| Non-small cell lung cancer stage IIIA/B |
Hsp70-peptide TKD/IL-2 activated |
Autologous |
Phase 2 |
18 – 75 years |
NCT02118415 |
| Leukaemia; Lymphoma; MM; HD |
N/A |
NK-92 cell line |
Phase 1 |
> 18 years |
NCT00990717 |
| Various |
IL-15 activated |
Autologous |
Phase 1 |
2 – 25 years |
NCT01875601 |
